“This novel testing provides insight into whether or not a patient will experience the anticipated effect of a prescribed medication or be at increased risk for additional side effects,” said Howard Appel, president of Millennium Laboratories.
The testing will help physicians determine if the dosing and selection of certain drugs — including methadone, benzodiazepines and tricyclic antidepressants — should be modified to better suit the patient’s tolerance level.
Related Articles on Pain Management:
8 New Pain Management Program Launches, Acquisitions or Developments
Iowa Patients Lack Treatment Options After Pain Clinic Shutters
New Hampshire Prescribing Fewer Painkillers for Inmates
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.